press-releases

Sep 04, 2024, 16:30 ET CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management’s participation in the H.C. Wainwright 26th Annual Global Investment Conference […]

Aug 13, 2024, 16:01 ET –         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis –         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design –         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 –         Webcast of Earnings Call

Aug 07, 2024, 16:30 ET CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August

May 21, 2024, 08:00 ET DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial  CUPERTINO, Calif., May 21, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute

May 13, 2024, 16:05 ET –         FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis –         Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31,

04 Mar, 2024, 07:00 ET Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ — DURECT